Printer Friendly

COURT UPHOLDS GLAXO ZANTAC PATENT

 RESEARCH TRIANGLE PARK, N.C., Sept. 17 /PRNewswire/ -- A U.S. District Court has today ruled in favor of Glaxo (NYSE: GLX) in its patent infringement lawsuit against Novopharm, a Canadian generic drug company.
 Judge Terrence Boyle's ruling upholds the validity of Glaxo's patent on Form 2 ranitidine hydrochloride, the active ingredient in Zantac(R), the world's most widely used ulcer medication and the best selling prescription medicine in the world. The ruling prevents Novopharm from marketing a generic version of Form 2 ranitidine (the form that Glaxo sells throughout the world) in the United States until 2002 when the Form 2 patent expires.
 Glaxo said the ruling vindicates its position that the U.S. patent on Form 2 ranitidine hydrochloride is valid until its expiration in June 2002.
 The court ruled that Novopharm had failed to show that the Form 2 patent was inherently disclosed in the basic patent. Further, Novopharm had failed to prove that Glaxo was guilty of any impropriety in the filing of the patent. (Novopharm had asserted that Glaxo was guilty of inequitable conduct in the filing of the patent and that it had concealed the best mode of using the patent.)
 Glaxo sued Novopharm in November 1991 when Novopharm filed an Abbreviated New Drug Application with the U.S. Federal Drug Administration, seeking permission to market a generic version of Form 2 ranitidine hydrochloride on expiration of Glaxo's basic patent in December 1995.
 Under U.S. patent law, it is presumed that a patent granted by the U.S. Patent Office is valid. Novopharm therefore bore the burden of proof in the case. The trial was held in the U.S. District Court for the Eastern District of North Carolina, from Aug. 9 - 18, 1993.
 Glaxo is an international research-based group of companies whose corporate purpose is the discovery, development, manufacture and marketing of safe, effective medicines of the highest quality. It currently spends over 700 million pounds sterling (US$1 billion) per year on research and development.
 -0- 9/17/93
 /CONTACT: Geoffrey Potter, 011-44-58-276-8100, or Martin Sutton, 011-44-49-467-2068 (press); Rick Sluder, 919-248-2839 or 919-967-6718 (U.S. press); or Penney Burnett, CFA, 212-308-5185, or Sheryl Sumner, 011-44-71-493-4060 (analyst/investor), all for Glaxo/
 (GLX)


CO: Glaxo Inc. ST: North Carolina IN: MTC SU:

GK-LD -- NY054 -- 3303 09/17/93 20:11 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 17, 1993
Words:388
Previous Article:J.M. PETERS COMPANY INC. NEWS RELEASE
Next Article:FOREST FAMILIES BETRAYED BY ENVIRONMENTALIST 'OFFER'
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters